Table 4.
Cost-effectiveness of CS in different studies
| Study | Klein | Weltert | Ours | Shander and Weltert |
|---|---|---|---|---|
| Country | Britain | Italy | China | Developed countries (Italy, Britain, America, Switzerland, Austria) |
| Year | 2007 | 2012 | 2014 | 2012(Italy), 2007(others) |
| Cases | 94 | 537 | 72 | / |
| Bleeding-risk of surgery | Low | Low and high | High | High |
| Price of allogeneic RBC ($/U)A | 219 | 201 | 22.8 | 203 |
| Quantity of autologous RBC transfusion (U)B | / | 1.95 | 4.09 | 4.09 |
| Price of autologous blood transfusion ($)C | 153 | 258 | 243.9 | 258 |
| Cost of reduced ($) D | -103 | 134 | -150.6 | 572.3 |
| Cost-effectiveness | No | Yes | No | Yes |
Data represent average quantity or cost per case. “ / ” = No data.
D = A×B - C or from the report ( Klein). Cost-effectiveness, D>0 = yes, D<0 = no.